查詢結果分析
相關文獻
- 基礎胰島素與Sitagliptin療效比較
- 第2型糖尿病之降血糖藥物治療
- 新診斷第2型糖尿病的短期胰島素強化治療
- 以Incretin為基礎的治療以及Sitagliptin (Januvia®)的使用時機
- ACARBOSE使用於口服降糖藥物失效之第2型糖尿病患者--臨床評估
- Effects of Insulin therapy on Non-Insulin-Dependent Diabetics with Secondary Oral Hypoglycemic Agent Failure
- Metformin--治療非胰島素依賴型糖尿病之降血糖藥物
- 糖尿病患低血糖之護理
- 糖尿病控制之進展與趨勢
- 以Glipizide治療對胰島素依賴型糖尿病患者葡萄糖注射之反應
頁籤選單縮合
題 名 | 基礎胰島素與Sitagliptin療效比較=Comparing the Efficacy of Basal Insulin with Sitagliptin |
---|---|
作 者 | 黃美嫆; 黃金鈴; 汪忠炫; 黃炳文; | 書刊名 | 藥學雜誌 |
卷 期 | 29:1=114 2013.03[民102.03] |
頁 次 | 頁90-94 |
分類號 | 418.271 |
關鍵詞 | 第2型糖尿病; 胰島素; 降血糖藥物; Type 2 diabetes mellitus; Basal insulin; Sitagliptin; Dipeptidyl peptidase-4 inhibitors; Hemoglobin; HbA1c; |
語 文 | 中文(Chinese) |
中文摘要 | 研究目的為比較 basal insulin 與 sitagliptin 在第2型糖尿病人之糖化血色素變化,以探討病人藥品療效。透過回溯性方法收集2009年6月至10月,51名血糖控制不佳併用 sitagliptin 100 mg/day 之病人,比較前後糖化血色素 (HbA1c) 及飯前血糖 (FPG) 之變化。追蹤2011年4月至6月338位 basal insulin 與233位 sitagliptin 的 HbA1c 及 FPG 值,以 SPSS17 進行資料統計分析。結果發現 用 sitagliptin 100 mg/day 12-16週後,FPG 由190.4 mg/dL 降至165.2 mg/dL (p=0.016);HbA1c 由9.1%降至8.2% (p=0.003)。Basal insulin 與 sitagliptin 治療後的 FPG 分別為195.3 mg/dL;156.9 mg/dL;HbA1c 分別為9.9 %;8.1%,兩者差異具統計意義 (p=0.000,0.000)。建議評估病人胰島素功能,早日投與 DPP-4 抑制劑藥品可延緩病情惡化及需要使用胰島素時間。藥師應衛教病人提升遵醫囑性並強調接受胰島素治療對血糖改善的優點,以減低糖尿病的惡化而導致身體其他器官功能受損。 |
英文摘要 | The aim of this study is to investigate the efficacy of basal insulin compared with the sitagliptin in type 2 diabetes mellitus. We conducted a retrospective study and collected data from June to Oct. 2009. The 51 patients with adding once-daily sitagliptin 100 mg for 12-16 weeks to concomitant anti-diabetes medicine therapy. The efficacy analysis of changes in fasting plasma glucose (FPG) and hemoglobin (HbA1c) from baselines was followed up from Apr. to Jun. 2011. We collected 338 patients with basal insulin and 233 patients with sitagliptin therapy. After 12-16 weeks, combination sitagliptin therapy significantly decreased FPG (from 190.4 decreased to 165.2 mg/dL, p=0.016) and HbA1c (from 9.1% decreased to 8.2%, p=0.003). Comparing with basal insulin group, sitagliptin significantly lowered in FPG (156.9 mg/dL versus 195.3 mg/dL, p=0.000) and HbA1c (8.1% versus 9.9%, p=0.000)。In our study we found sitagliptin significantly improved HbA1c control. Long term follow-up research to find that DPP-4 inhibitor provide better glycemic control and improve the diabetes related complications. |
本系統中英文摘要資訊取自各篇刊載內容。